Bortezomib is an anti-neoplastic drug acting against multiple myeloma but its use is associated with the onset of painful peripheral neuropathy. Tumor necrosis factor-α (TNFα) is associated with the development of neuropathic pain; several models have shown that the inactivation of TNFα leads to a reduction in pain stimuli perception. The aim of the present study was to analyze if the administration of an antibody against TNFα is able to prevent the development of bortezomib-induced neuropathic pain.
Chiorazzi, A., Canta, A., Meregalli, C., Carozzi, V., Sala, B., Oggioni, N., et al. (2013). Antibody Against Tumor Necrosis Factor-α Reduces Bortezomib-induced Allodynia in a Rat Model. ANTICANCER RESEARCH, 33(12), 5453-5459.
Antibody Against Tumor Necrosis Factor-α Reduces Bortezomib-induced Allodynia in a Rat Model
CHIORAZZI, ALESSIA;CANTA, ANNALISA ROSANNA;MEREGALLI, CRISTINA;CAROZZI, VALENTINA ALDA;SALA, BARBARA;OGGIONI, NORBERTO;CAVALETTI, GUIDO ANGELO
2013
Abstract
Bortezomib is an anti-neoplastic drug acting against multiple myeloma but its use is associated with the onset of painful peripheral neuropathy. Tumor necrosis factor-α (TNFα) is associated with the development of neuropathic pain; several models have shown that the inactivation of TNFα leads to a reduction in pain stimuli perception. The aim of the present study was to analyze if the administration of an antibody against TNFα is able to prevent the development of bortezomib-induced neuropathic pain.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
